Apogee Therapeutics reported that its anti‑IL‑13 antibody zumilokibart (APG777) achieved durable maintenance of response in its Phase 2 APEX Part A trial. At 52 weeks, 75 % of patients on the 3‑month dosing schedule and 85 % on the 6‑month schedule maintained an EASI‑75 response, while 86 % and 78 % maintained a vIGA 0/1 score, respectively. The data also showed continued deepening of efficacy across all lesion and itch endpoints and a safety profile consistent with other biologics in the class.
The 52‑week results support the potential for quarterly or even biannual dosing, a key differentiator in the atopic dermatitis market. Zumilokibart also achieved greater than 99 % inhibition of IL‑13, underscoring its mechanism‑based potency.
Management highlighted the significance of the data, stating, "Our 52‑week Part A data mark a significant milestone for zumilokibart, with the potential to transform the treatment paradigm as the first 6‑month dosed therapeutic for patients with AD." The CEO also noted, "Importantly, we observed continued deepening of efficacy across all endpoints for both 3‑ and 6‑month dosing through 52 weeks in the full zumilokibart treated population, not just 16‑week responders, while standard of care treatments typically plateau."
Phase 2 Part B induction data are expected in the second quarter of 2026, and Phase 3 trials are slated to begin later this year. Apogee will present the full data set at the 2026 American Academy of Dermatology Annual Meeting (March 27‑31) and will host a conference call on March 23 to discuss the results.
Apogee is a pre‑revenue company; its most recent earnings report (Q4 2025) showed a net loss per share of –$1.03 and $902.9 million in cash, cash equivalents, and marketable securities as of December 31 2025. The cash runway is expected to fund operations into the second half of 2028, providing sufficient runway through the planned Phase 3 milestones and a potential commercial launch in 2029.
The 52‑week maintenance data reinforce Apogee’s strategy of developing a differentiated, less‑frequently dosed therapy for atopic dermatitis, positioning the company to capture a share of a multi‑billion‑dollar market that is expanding as new IL‑13 inhibitors enter the field. The durable response and potential for biannual dosing could offer a competitive advantage over existing therapies that require more frequent administration.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.